CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.

Amanda Smith, registered nurse, of Huntsman Cancer Institute, helped lead novel research on MPN drug safety during pregnancy, earning co-authorship and her mentor's highest praise.

Independent radiology review showed 94% ORR (15% CR) in 94 TKI-naïve ROS1+ NSCLC patients receiving 100 mg daily, with median DoR and PFS not reached. Central nervous system efficacy was robust: 10/10 ...

Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

I have been living with stage IV kidney cancer for more than ten years. By now, I have had more CT scans, MRIs, PET scans, blood tests and follow-up appointments than I could ever count. You would ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

Expanded timing includes annual MRD testing during maintenance and after subsequent therapy lines, including following CAR-T, to enable serial assessment rather than single timepoint interpretation.

Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.

Local transplant availability reduced patient travel burden and preserved continuity for long-term oncology relationships, reinforcing the program’s mission around access and community-based care.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...